ESSA Pharma Inc
EPIX
View Detailed Chart
0.201USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
8.93MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
-88.37%
Year to Date
-88.76%
1 Year
-87.42%
View Detailed Chart
TradingKey Stock Score of ESSA Pharma Inc
Currency: USD Updated: 2025-10-09Key Insights
Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at max_target_price.
ESSA Pharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
1.700
Target Price
+744.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ESSA Pharma Inc Highlights
StrengthsRisks
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 34.87M shares, decreasing 27.83% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 15.75.
ESSA Pharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ESSA Pharma Inc Info
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Ticker SymbolEPIX
CompanyESSA Pharma Inc
CEODr. David Ross Parkinson, M.D.
Websitehttps://www.essapharma.com/
FAQs
What is the current price of ESSA Pharma Inc (EPIX)?
The current price of ESSA Pharma Inc (EPIX) is 0.201.
What is the symbol of ESSA Pharma Inc?
The ticker symbol of ESSA Pharma Inc is EPIX.
What is the 52-week high of ESSA Pharma Inc?
The 52-week high of ESSA Pharma Inc is 0.825.
What is the 52-week low of ESSA Pharma Inc?
The 52-week low of ESSA Pharma Inc is 0.173.
What is the market capitalization of ESSA Pharma Inc?
The market capitalization of ESSA Pharma Inc is 8.93M.
What is the net income of ESSA Pharma Inc?
The net income of ESSA Pharma Inc is -28.54M.
Is ESSA Pharma Inc (EPIX) currently rated as Buy, Hold, or Sell?
According to analysts, ESSA Pharma Inc (EPIX) has an overall rating of --, with a price target of 1.700.
What is the Earnings Per Share (EPS TTM) of ESSA Pharma Inc (EPIX)?
The Earnings Per Share (EPS TTM) of ESSA Pharma Inc (EPIX) is -0.569.
Related Instruments
0.00%
+0.63%
+3.82%
-1.78%
-0.10%
0.00%
+0.57%
0.00%
+0.10%
0.00%
-0.04%
+1.08%
-0.14%
0.00%
+0.11%
+0.02%
0.00%
+0.10%
-0.05%
+1.18%
